Methods for Assessing the Susceptibility of a Human to Diminished Health and Wellness

A method of assessing the advisability that a human should employ a compensatory composition, the method comprised of

• a) obtaining a biological sample from the human
• b) assessing occurrence in the human's genome of a plurality of polymorphisms wherein the plurality of polymorphisms consists of at least four of of
• i) a polymorphism manifested as a change from a thymine residue to a cytosine residue at amino acid residue 16 of mitochondrial superoxide dismutase 2 (MnSOD2);
• ii) a polymorphism manifested as a change from a cytosine residue to a thymine residue at amino acid residue 198 of glutamate peroxidase 1 (GPX1);
• iii) a polymorphism manifested a change from a thymine residue to a cytosine residue at amino acid residue 113 in exon 3 of microsomal epoxide hydrolase 1 (mEPHX1);
• iv) a polymorphism manifested as a change from an adenine residue to a guanine residue at amino acid residue 192 of paraoxonasel (PON1);
• v) a polymorphism manifested as a change from a cytosine residue to a thymine residue at amino acid residue 222 of 5,10-methylenetetrahydrofolate reductase (MTHFR) resulting in an alanine to valine substitution;
• vi) a polymorphism manifested as a change from an adenine residue to a guanine residue at amino acid residue 22 of methionine synthase reductase (MTRR);
• vii) a polymorphism manifested as a change from an adenine residue to a guanine residue at amino acid residue −308 of tumor necrosis factor alpha (TNFa);
• viii) a polymorphism manifested as the presence of a guanine at amino acid residue −1607 of matrix metallproteinase 1 (MMPI)
• ix) a polymorphism manifested as a change from a guanine nucleotide to an adenine nucleotide in exon 2, producing a new translational start site such that the length of the variant vitamin d (1,25-dihydroxyvitamin D3) receptor (VDR) is increased by three amino acids;
• x) a polymorphism manifested as a change from a cytosine residue to a thymine residue at amino acid residue 187 of NAD(P)H:dehydrogenase, quinine 1 (NQO1);
• xi) a polymorphism manifested as a change from a cytosine residue to a thymine residue at amino acid residue −344 of cytochrome P450, family 11, subfamily B, polypeptide 2 (CYP11B2);
• xii) a polymorphism manifested as a change from a cytosine residue to a thymine residue at amino acid residue 2514 of apolipoprotein B (ApoB);
• and
• c) providing an instructional material to the human wherein a human whose genome contains one or more disadvantaged alleles as determined by assessment of the polymorphisms selected from the panel is advised to employ a compensatory composition comprised of one or more antioxidants.